Brukinsa

Active Ingredient(s): Zanubrutinib
FDA Approved: * November 14, 2019
Pharm Company: * BEIGENE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Brukinsa Overview

Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[3] It was approved for medical use in the United States in November 2019.[4][3][5][6] Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.[7] It is administered orally.[7] History Efficacy was e...

Read more Brukinsa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Zanubrutinib

Recent Brukinsa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Zanubrutinib
  • Capsule: 80mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Brukinsa: (1 result)

Sorted by National Drug Code
  • 72579-011 Brukinsa 80 mg Oral Capsule, Gelatin Coated by Beigene USA, Inc.

Other drugs which contain Zanubrutinib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 October 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA